Amarin announces presentation of research on clinical impact of VASCEPA/VAZKEPA

Amarin Corporation announced that new supported and/or funded research on the clinical impact of VASCEPA/VAZKEPA in patients with diabetes and high cardiovascular risk and the anti-Lp(a) oxidation mechanistic effects of eicosapentaenoic acid will be presented at the 60th Annual European Association for the Study of Diabetes Meeting September 9 – 13, 2024 in Madrid, Spain. The two accepted abstracts, which will be presented by international academic collaborators who have partnered with Amarin, include: A post-hoc analysis from the REDUCE-IT trial examining the effect of VASCEPA/VAZKEPA on a subgroup of patients with established cardiovascular disease and diabetes mellitus at baseline with a history of coronary artery bypass grafting surgery; and An in-vitro analysis of EPA and its effects on lipoprotein(a) oxidation under normal and high glucose conditions that reproduce hyperglycemia in vivo. “As has been well-proven, patients with established cardiovascular disease and diabetes mellitus are at increased risk of future cardiovascular events, especially in patients with elevated levels of Lp(a), making it the main cause of mortality among these patients.” said Nabil Abadir, Chief Medical Officer. “It is therefore imperative that we continue to focus on and invest in science to better understand different therapies that can have a potential impact on helping these patients reduce their risk of yet another cardiovascular event. We remain committed to partnering with cardiovascular researchers to further our understanding of icosapent ethyl and EPA and their potential impact on reducing cardiovascular risk in this vulnerable patient sub-population.”